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Summary 
 
Frontotemporal dementia (FTD) encompasses the syndromes of behavioural variant FTD 
(bvFTD) and primary progressive aphasia (PPA) and refers to those neurodegenerative 
diseases characterised by predominant pathological involvement of the frontal and 
temporal lobes. Recent years have witnessed major advances in the clinical 
characterisation of FTD, reflected in the publication of updated diagnostic criteria for 
bvFTD and PPA, and the discovery of new pathogenic mutations has added to the 
understanding of genotype-phenotype interactions and of disease mechanisms. Emerging 
results from longitudinal studies of familial FTD show that imaging and cognitive changes 
occur years before symptom onset and such studies may yield biomarkers of early disease 
that in turn will facilitate earlier diagnosis.  
The hope and (guarded) expectation is that these advances may together herald the 
beginning of the end of the chapter in which FTD is considered an inexorably progressive 
and untreatable condition.  
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1. Introduction 
Frontotemporal dementia (FTD) is a term encompassing a variety of clinical syndromes 
which collectively are characterised by dysfunction, atrophy and/or hypometabolism of the 
frontal and temporal lobes. The neurodegeneration underlying FTD results from 
heterogeneous molecular pathologies, unified under the umbrella pathological term 
“frontotemporal lobar degeneration” (FTLD). This article will review the progress made in 
the field of FTD over the last few years, such as the publication of new consensus 
diagnostic criteria and the identification of new pathogenic mutations. Preclinical studies of 
FTD, such as the recent work on novel mouse models of FTD, will not be covered in this 
review. 
2. Nosology and diagnosis 
The previous 1998 Neary et al. criteria [1] described three syndromic variants associated 
with FTLD (frontotemporal dementia, progressive non-fluent aphasia and semantic 
dementia). By comparison, the current clinical classifications which divide FTD into two 
main syndromes: behavioural variant frontotemporal dementia (bvFTD) and primary 
progressive aphasia (PPA), with the latter further divided into subtypes on the basis of 
differences in the nature of the speech and language disorder [2]. In addition to these 
revised classifications, the clinical diagnostic categorisation has expanded to encompass 
the idea of an overlap syndrome between FTD and amyotrophic lateral sclerosis (ALS), 
given the identification of shared pathogenic mutations [3, 4], ALS-type motor 
abnormalities in 14% of FTD patients [5], and symptoms of FTD in 15-18% of ALS patients 
[6]. 
FTD has long been considered primarily a young onset dementia. However, this has 
recently been cast into question, with 48% of FTD patients found to be aged 65 years or 
older at presentation [8]. 
 
The underlying FTLD pathology can be divided into three main groups based on the 
predominant intracellular protein aggregate: FTLD-tau, FLTD-TDP and FTLD-FUS [7]. In 
addition to FTD these pathologies are also found to underlie corticobasal syndrome and 
progressive supranuclear palsy. The clinicopathological correlation between FTD and 
FTLD is variable; for example, there is a correlation between FTD with ALS and FTLD-
TDP, and between semantic variant PPA and FTLD-TDP, whereas by comparison bvFTD 
does not correlate with any particular neuropathological subtype [7]. Certain pathogenic 
mutations are also associated with particular pathologies, notably between MAPT 
mutations and FTLD-tau pathology, and between C9orf72 hexanucleotide repeat 
expansions and FTLD-TDP pathology (see section 4 for more details). 
2.1. Behavioural variant FTD (bvFTD) 
The 2011 revised international consensus criteria for bvFTD [9] classify the disease as 
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possible bvFTD (as diagnosed on the basis of behavioural and cognitive symptoms 
supported by neuropsychological findings), probable bvFTD (possible bvFTD AND 
functional decline and imaging changes in the form of frontal and/or anterior temporal lobe 
atrophy/hypometabolism/hypoperfusion), or definite bvFTD (possible or probable FTD 
AND either histopathological evidence of FTLD or a confirmed pathogenic mutation). 
These criteria are outlined in full in Table 1 (below): 
Table 1: International consensus criteria for behavioural variant FTD (FTDC) (adapted from Rascovsky et al. 
[9]).  
Possible bvFTD 
At least three of the following clinical features: 
Early* behavioural disinhibition  
(socially inappropriate behaviour OR loss of manners or decorum OR impulsive, rash or careless actions) 
Early apathy or inertia 
Early loss of sympathy or empathy  
(diminished response to other people’s needs and feelings OR diminished social interest, interrelatedness or personal warmth) 
Early perseverative, stereotyped or compulsive/ritualistic behaviour  
(simple repetitive movements OR complex, compulsive or ritualistic behaviours OR stereotypy of speech) 
Hyperorality and dietary changes  
(altered food preferences OR binge eating, increased consumption of alcohol or cigarettes OR oral exploration or consumption of 
inedible objects) 
Neuropsychological profile: executive/generation deficits with relative sparing of memory and visuospatial functions 
(deficits in executive tasks AND relative sparing of episodic memory AND relative sparing of visuospatial skills) 
Probable bvFTD 
Meets criteria for possible bvFTD and both of: 
Significant functional decline  
(by caregiver report or as evidenced by Clinical Dementia Rating Scale or Functional Activities Questionnaire scores) 
Imaging results consistent with bvFTD  
(frontal and/or anterior temporal atrophy on MRI or CT OR frontal and/or anterior temporal hypoperfusion or hypometabolism on PET or 
SPECT) 
bvFTD with definite FTLD Pathology 
Meets criteria for possible or probable bvFTD and one of: 
Histopathological evidence of FTLD on biopsy or at post-mortem 
Presence of a known pathogenic mutation 
Exclusionary criteria for bvFTD 
The following must be negative for any bvFTD diagnosis: 
Pattern of deficits is better accounted for by other non-degenerative nervous system or medical disorders 
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Behavioural disturbance is better accounted for by a psychiatric diagnosis 
The following can be positive for possible bvFTD but must be negative for probable bvFTD: 
Biomarkers strongly indicative of Alzheimer’s disease or other neurodegenerative process 
*Early refers to symptom presentation within the first 3 years 
The validity of these new bvFTD criteria has been assessed with a clinicopathological 
brain bank-based study of diagnostic sensitivity. Of 137 pathologically confirmed cases, 
86% met criteria for possible bvFTD and 76% for probable bvFTD, representing a 
significant improvement in sensitivity compared to previous criteria [9]. A subsequent 
retrospective series looking at presenting features of pathologically confirmed cases found 
high sensitivity and specificity (possible FTD: sensitivity 95% for specificity 92%; probable 
FTD: sensitivity 85% for specificity 95%)[10].  
Despite these revised criteria, accurate clinical diagnosis of bvFTD can remain challenging 
and can be hard to distinguish from two particular disorders on clinical grounds alone. The 
first of these is “bvFTD phenocopy syndrome” [11]. Patients with this syndrome exhibit the 
clinical features of bvFTD (and would thus fulfil criteria for the diagnosis of possible 
bvFTD) but fail to show progressive functional decline, neuroimaging changes or 
neuropathological changes consistent with FTLD, and have a much better prognosis. The 
cause of bvFTD phenocopy syndrome is unclear, but this is likely to be heterogeneous and 
in some instances may be representative of a decompensated personality disorder or 
subclinical autism spectrum disorder [11]. However, comprehensive neuropsychiatric and 
neuropsychological profiling may help differentiate bvFTD and bvFTD phenocopy 
syndrome and the need for caution in attributing the latter diagnosis is underscored by the 
observation that two (related) cases diagnosed independently with phenocopy syndrome 
were found to tested positive for c9orf72 [12]. 
The second diagnosis that can be confused with bvFTD is “frontal” or 
“behavioural/dysexecutive” variant of Alzheimer's disease (AD), representing one of three 
non-amnestic variants of AD specified in the updated AD diagnostic criteria [13]. In 
contrast to the typical AD presentation with memory impairment, the cognitive impairment 
in this instance is manifest primarily as impaired reasoning, judgment, and problem 
solving. The difficulty of distinguishing clinically between bvFTD and 
behavioural/dysexecutive variant AD is illustrated by a study showing that 52% of patients 
with pathologically- or biomarker-confirmed AD who presented with a behavioural or 
dysexecutive-predominant presentation met current criteria for possible bvFTD [14]. 
However, despite clinical similarities, these patients have different patterns of atrophy to 
bvFTD patients, with marked bilateral temporoparietal atrophy and limited frontal lobe 
atrophy [14].  
2.2. Primary progessive aphasia (PPA) 
PPA is characterised by the progressive impairment of speech production, naming, syntax 
and/or word comprehension with initial relative preservation of other cognitive functions, 
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and current diagnostic criteria are based on those described by Mesulam [15]. In 2011, 
consensus diagnostic criteria for PPA subtypes were published for the first time and these 
divide PPA into three groups: semantic variant PPA (svPPA), nonfluent variant PPA 
(nfvPPA) and logopenic variant PPA (lvPPA) [2]. When compared with the FTD syndromic 
variants described in the 1998 Neary et al. criteria [1], svPPA and nfvPPA are considered 
to be broadly analogous to “semantic dementia” and “progressive non-fluent aphasia”. 
However this concordance is not exact, as exemplified by a retrospective case series 
which found 51% of cases previously diagnosed as progressive non-fluent aphasia were 
reclassified as lvPPA rather than nfvPPA [16]. Research into clinicopathological 
correlations has found that the most common pathology in patients clinically diagnosed 
with lvPPA was AD [16, 17] and lvPPA is now considered an AD, rather than FTD, 
subtype.  
Table 2: Diagnostic criteria for nfvPPA and svPPA (adapted from Gorno-Tempini et al. [2]). 
nfvPPA svPPA 
Clinical diagnosis 
At least one of the following core features: Both of the following core features: 
Agrammatism in language production Impaired confrontation naming 
Apraxic speech (effortful, halting speech with sound 
errors) 
Impaired single word comprehension 
At least 2 of 3 of the following other features: At least 3 of 4 of the following other features: 
Impaired comprehension of syntactically complex 
sentences 
Impaired object knowledge, particularly for low frequency 
items 
Spared single word comprehension Surface dyslexia or dysgraphia 
Spared object knowledge Spared repetition 
 Spared speech production (grammar and motor speech) 
Imaging-supported diagnosis  
clinical diagnosis plus at least one of: 
Predominant left posterior fronto-insular atrophy on MRI Predominant anterior temporal lobe atrophy 
Predominant left posterior fronto-insular hypoperfusion or 
hypometabolism on SPECT or PET 
Predominant anterior temporal lobe hypoperfusion or 
hypometabolism on SPECT or PET 
Definite pathology 
Clinical diagnosis plus one of: 
Histopathological evidence of a specific neurodegenerative pathology (e.g. FTLD-tau, FTLD-TDP, AD, other) 
Presence of a known pathogenic mutation 
6 
 
Some questions persist about the ability of these proposed PPA subtypes to encompass 
all presentations with progressive aphasia, with Sajjadi et al. [18] noting that 41% of 46 
patients with PPA did not meet diagnostic criteria for any of the three PPA subtypes. 
2.3. “Right temporal” FTD  
One anatomical variant of FTD not fully captured by the reformulated bvFTD and PPA 
clinical classifications is that in which pathology predominantly affects the right temporal 
lobe. This has been variously described as “right temporal variant FTD” [19, 20] and “right 
temporal lobe atrophy” [21]. Two clinical subtypes of “right temporal FTD” have been 
described to date. Patients with “right temporal” bvFTD typically present with behavioural 
disorders and personality change, with additional frontal lobe atrophy. In these cases tau is 
the predominant pathology. By comparison, patients with “right temporal” semantic 
dementia [sic] exhibit topographical disorientation, prosopagnosia and impaired word 
comprehension, with minimal frontal lobe atrophy and TDP-43 as the main underlying 
pathology [22]. 
3. Cognition 
Outside of the dysexecutive syndrome and the disruption of speech and language that are 
central to the cognitive profiles of bvFTD and PPA respectively, significant recent attention 
has been devoted to the nature of memory deficits in these disorders. Episodic memory is 
considered to be relatively preserved in bvFTD (and in fact is one of the diagnostic criteria) 
but there is evidence to suggest that it is similarly impaired in both AD and bvFTD [23], 
possibly as a result of anterior hippocampal involvement in bvFTD, and that the previously 
reported preservation of episodic memory may reflect in part the incorrect inclusion of 
patients with bvFTD phenocopy [24]. By comparison, allocentric spatial memory and 
spatial orientation are relatively preserved in bvFTD but impaired in AD [25, 26], likely 
reflecting the sparing of the precuneus and posterior hippocampus in bvFTD, and this 
information may help in the differential diagnosis of these disorders.  
Emerging information on the initial cognitive changes in FTD are being obtained from the 
GENFI study (GENetic FTD Initiative) which has shown impairment on tests of executive 
function and naming five years prior to anticipated symptom onset [27]. 
4. Imaging 
FTD variants are characterised by imaging changes affecting the frontal and/or temporal 
lobes in the form of atrophy, hypometabolism and hypoperfusion and such imaging 
abnormalities are listed within the diagnostic criteria for both bvFTD and PPA. In familial 
FTD, the onset of atrophy significantly predates symptoms, with mutation carriers found to 
have significant reduction in insular and temporal lobe volume 10 years prior to anticipated 
symptom onset [27]. 
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Figure 1 
Simultaneously acquired PET-MRI scans in sagittal (left), axial (middle) and coronal (right) 
sections. Top panel: behavioural variant FTD. Atrophy and hypometabolism are maximal in the 
frontal and anterior temporal lobes bilaterally. Bottom panel: semantic variant PPA. Atrophy and 
hypometabolism are maximal in the left temporal lobe. 
 
Much of the more recent imaging research in FTD has focused on determination of 
changes in brain structural and functional connectivity. Diffusion tensor imaging has shown 
progressive disruption of white matter tracts in all FTD subtypes [28, 29], with reduced 
tract integrity correlating with symptom progression [30]. The observation that white matter 
pathways are impaired in presymptomatic mutation carriers indicates that disruption of 
structural connectivity is an early feature of FTD [31, 32]. 
Resting state (“task-free”) functional MRI studies have found that FTD syndromes are 
associated with disruption of different functional brain networks [33]. In bvFTD there is 
reduced functional connectivity within the frontal lobe-predominant network considered to 
underpin emotional salience [34, 35]. Changes in nonfluent variant PPA are found within a 
predominantly left-hemisphere network encompassing the frontal operculum, 
supplementary motor cortex and inferior parietal lobule, consistent with the complementary 
roles of these brain regions in the generation of fluent speech, whereas the functional 
brain network implicated in semantic variant PPA involves the temporal poles, ventral 
striatum and amygdala [33]. 
5. CSF biomarkers 
Testing of CSF is not currently used in routine clinical practice to diagnose FTD although 
analysis of CSF AD biomarkers (Aβ1-42 and tau) can help differentiate AD from FTD, with 
CSF  Aβ1-42 associated with a sensitivity of 77% for diagnosing AD against FTD for a 
specificity of 95% [36].  
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CSF neurofilament light chain (NfL) levels may represent a possible future biomarker of 
FTD. These have been found to be significantly higher in FTD than AD or controls and 
levels correlate with performance on neuropsychological tests and with frontal/temporal 
atrophy [37], although their sensitivity and specificity remain to be determined. NfL levels 
have recently been shown to distinguish ALS and controls with a high level of sensitivity 
and specificity and to be a strong independent predictor of survival [38], and this may have 
relevance for FTD given the neuropathological overlap between ALS and FTD.    
6. Genetics and molecular pathology  
Approximately 40% of FTD patients have a positive family history of disease [39], and 10-
25% of family pedigrees are associated with an autosomal dominant pattern of inheritance 
[40, 41]. The commonest pathogenic mutations in FTD affect the C9orf72, MAPT and GRN 
genes, which together account for 10-20% of all FTD cases [42].  
Arguably the most important recent advance in the field of FTD genetics is the discovery 
that an abnormal expansion of a hexanucleotide repeat in the C9orf72 gene accounts for 
25% of familial and 6% of sporadic FTD cases [43–45] and also accounts for 30-50% and 
5-7% of familial and sporadic ALS respectively [44]. Other less frequent mutations 
common to both FTD and ALS have been found, such as mutations in he VCP and 
CHCHD10 genes (see Table 3). TDP-43 positive inclusions are found in the CNS of 
patients with both ALS and FTD [46]. 
Table 3: Genes associated with FTD (adapted from Guerreiro et al. [3]) 
Mendelian genes 
FTD Possible pathway FTD/ALS Possible pathway 
MAPT Toxic aggregation (defect in neuronal 
cytoskeleton) 
C9orf72 Toxic RNA or repeat dipeptides 
aggregation 
GRN Autophagy; lysosomal pathway; 
inflammation 
SQSTM1 Autophagy 
CHMP2B Autophagy; lysosomal pathway UBQLN2 Autophagy 
TREM2 Inflammation VCP Autophagy 
PRKAR1B Regulation of metabolism, ion 
transport, and gene transcription 
OPTN Autophagy 
  CHCHD10 Mitochondrial function 
  HNRNPA1 RNA metabolism; direct interaction with 
TDP-43 
  HNRNPA2B1 RNA metabolism; direct interaction with 
TDP-43 
  SIGMAR1 Endoplasmic reticulum lipid rafts 
Examples of risk modifier genes 
TMEM106B Regulation of lysosomal function and 
progranulin pathways 
ATXN2 Modifier of TDP-43 toxicity 
 
Several genetic variants have been shown to modify disease risk or disease phenotype 
and patients carrying variants in more than one gene have been described. This has led to 
the oligogenic hypothesis which postulates that the presence of various mutations can 
modify the phenotype (e.g. presence of motor features/cognitive impairment) and clinical 
features such as survival and age of onset [4]. This is exemplified by the presence of the 
TMEM106B rs1990622 major allele which, in FTD patients with C9orf72 mutations, 
correlates with later age of disease onset and later age of death [47].  
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7. Treatments and current trials 
There are no disease-modifying treatments for FTD and the mainstay of management 
remains non-pharmacological care [48].  However, a small open-label study using 
citalopram to treat behavioural disturbance did find a significant improvement on measures 
of disinhibition, irritability and depression [49].  
A phase III study of a tau aggregation inhibitor is currently under way and is expected to 
report results in 2016 [50].  
8. Conclusions 
There have been significant recent advances in understanding the FTD syndromes and 
these are reflected in the publication of new diagnostic criteria for bvFTD and PPA 
subtypes. While an improvement on previous criteria, these remain work in progress and 
future studies will undoubtedly seek to address the current outstanding diagnostic 
challenges outlined in this review article. Ongoing and future work into molecular genetics 
and neuroimaging will aid in the phenotyping of FTD, and the planned further study of pre-
symptomatic mutation carriers, within programmes such as GENFI2, will hopefully deliver 
new biomarkers of early disease.  
Sadly, progress in developing disease-modifying drugs for the treatment of FTD remains 
slow. However, these advances in clinical understanding, when combined with 
developments in systems biology research into disease mechanisms, will provide a more 
robust framework for experimental medicine and, from there, the delivery of effective 
treatments for FTD. 
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